Get started
Author

James D. Wakefield

Modified-Peptide Inhibitors of Amyloid β-Peptide Polymerization
1999 · Mark A. Findeis, Gary M. Musso, et al. · Biochemistry · 225
Pharmacologic Properties, Metabolism, and Disposition of Linaclotide, a Novel Therapeutic Peptide Approved for the Treatment of Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation
2012 · Robert W. Busby, Marco M. Kessler, et al. · Journal of Pharmacology and Experimental Therapeutics · 139
Pharmacological Characterization of IW-1973, a Novel Soluble Guanylate Cyclase Stimulator with Extensive Tissue Distribution, Antihypertensive, Anti-Inflammatory, and Antifibrotic Effects in Preclinical Models of Disease
2018 · Jenny V. Tobin, Daniel P. Zimmer, et al. · Journal of Pharmacology and Experimental Therapeutics · 63
PDF
Effects of the Soluble Guanylate Cyclase Stimulator Praliciguat in Diabetic Kidney Disease: A Randomized Placebo-Controlled Clinical Trial
2020 · John P. Hanrahan, Ian H. de Boer, et al. · Clinical Journal of the American Society of Nephrology · 45
An exploratory, randomised, placebo-controlled, 14 day trial of the soluble guanylate cyclase stimulator praliciguat in participants with type 2 diabetes and hypertension
2019 · John P. Hanrahan, Jelena P. Seferovic, et al. · Diabetologia · 41
PDF
Fatty Acid Amide Hydrolase (FAAH) Inhibition Reduces l-3,4-Dihydroxyphenylalanine-Induced Hyperactivity in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Lesioned Non-Human Primate Model of Parkinson’s Disease
2010 · Tom H. Johnston, Philippe Huot, et al. · Journal of Pharmacology and Experimental Therapeutics · 40
Olinciguat, an Oral sGC Stimulator, Exhibits Diverse Pharmacology Across Preclinical Models of Cardiovascular, Metabolic, Renal, and Inflammatory Disease
2020 · Daniel P. Zimmer, Courtney M. Shea, et al. · Frontiers in Pharmacology · 35
PDF
Characterization of cholyl-leu-val-phe-phe-ala-OH as an inhibitor of amyloid beta-peptide polymerization
2001 · Mark A. Findeis, Jung-Ja Lee, et al. · Amyloid · 35
A Randomized, Placebo‐Controlled, Multiple‐Ascending‐Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Soluble Guanylate Cyclase Stimulator Praliciguat in Healthy Subjects
2018 · John P. Hanrahan, James D. Wakefield, et al. · Clinical Pharmacology in Drug Development · 33
PDF
Abstracts from the 8th International Conference on cGMP Generators, Effectors and Therapeutic Implications
2017 · on behalf of the Ironwood team, G. Todd Milne, et al. · BMC Pharmacology and Toxicology · 16
PDF
An inhibitor of methionine aminopeptidase type-2, PPI-2458, ameliorates the pathophysiological disease processes of rheumatoid arthritis
2008 · D. D. Lazarus, E. G. Doyle, et al. · Inflammation Research · 16
Metabolites of PPI-2458, a Selective, Irreversible Inhibitor of Methionine Aminopeptidase-2: Structure Determination and In Vivo Activity
2013 · Christopher C. Arico-Muendel, Bruce Belanger, et al. · Drug Metabolism and Disposition · 11
Pharmacokinetics, mass balance, tissue distribution, metabolism, and excretion of praliciguat, a clinical‐stage soluble guanylate cyclase stimulator in rats
2020 · Ali R. Banijamali, Andrew E. Carvalho, et al. · Pharmacology Research & Perspectives · 8
PDF
Fourteen-Day Study of Praliciguat, a Soluble Guanylate Cyclase Stimulator, in Patients with Diabetes and Hypertension
2018 · JOHN P. HANRAHAN, JAMES D. WAKEFIELD, et al. · Diabetes · 6
First-in-human Single-ascending-dose Study of Iw-1973, a New Soluble Guanylate Cyclase Stimulator
2016 · John Hanrahan, Albert T. Profy, et al. · Journal of the American College of Cardiology · 4
PDF
Metabolism and disposition of MM ‐433593, a selective FAAH ‐1 inhibitor, in monkeys
2014 · Ali R. Banijamali, James D. Wakefield, et al. · Pharmacology Research & Perspectives · 4
PDF
Rapid Dose Escalation Study of Praliciguat, a Soluble Guanylate Cyclase Stimulator, in Patients with Diabetes and Hypertension
2018 · JOHN P. HANRAHAN, JAMES D. WAKEFIELD, et al. · Diabetes · 2
Abstract P493: Multiple-ascending-dose Study of IW-1973, a Soluble Guanylate Cyclase Stimulator
2017 · John Hanrahan, James Wakefield, et al. · Hypertension · 2
Concomitant administration of sGC stimulators with common classes of anti-hypertensive agents results in increased efficacy in spontaneously hypertensive rats
2015 · Peter Germano, Jenny Tobin, et al. · BMC Pharmacology and Toxicology · 2
PDF
Effect of Praliciguat, a Once-Daily, Oral Soluble Guanylate Cyclase Stimulator, on Albuminuria in Patients with Diabetic Kidney Disease: A Randomized, Double-Blind, Phase 2 Trial
2020 · John P. Hanrahan, Ian H. de Boer, et al. · Journal of the American Society of Nephrology · 1
1073-P: Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Soluble Guanylate Cyclase Stimulator Praliciguat in Patients with Diabetic Kidney Disease
2020 · JOHN P. HANRAHAN, IAN DE BOER, et al. · Diabetes · 1
Quantitative Tissue Distribution and Pharmacokinetics of IW‐1973, a Novel Clinical‐Stage sGC Stimulator, After Oral Administration in Rats
2017 · Ali Banijamali, James Wakefield, et al. · The FASEB Journal · 1
Phagocytosis of beta-amyloid: A possible requisite for neurotoxicity
1998 · R. Weltzien, A. Andjelkovic, et al. · Journal of Neuroimmunology · 1
Quantitative mass balance, tissue distribution, pharmacokinetics and biotransformation pathway of praliciguat, a clinical-stage sgc stimulator, after oral administration in rats
2019 · Ali Banijamali, Andrew Carvalho, et al. · Drug Metabolism and Pharmacokinetics
Abstract 16938: IW-1973 is a Potent Soluble Guanylate Cyclase Stimulator in vitro and in vivo With Extensive Tissue Distribution
2016 · Daniel P. Zimmer, Jenny Tobin, et al. · Circulation
Works count: 26
Citation count: 731
H-index: 11
I10-index: 12
Year
Topic
Type